Search Results - Gary R. Cutter

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Final analysis of potential drug–drug interactions between highly purified cannabidiol and anti‐seizure medications in an open‐label expanded access program by Tyler E. Gaston, E. Martina Bebin, Gary R. Cutter, Leslie Grayson, Jerzy P. Szaflarski

    Published in Epilepsia Open (2023-12-01)
    Get full text
    Article


  2. 2

    Attitudes of people with multiple sclerosis toward brain donation by Ruth Ann Marrie, Ruth Ann Marrie, Leanne Kosowan, Gary R. Cutter, Robert J. Fox, Amber Salter

    Published in Frontiers in Neurology (2023-01-01)
    Get full text
    Article


  3. 3

    The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives by Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, Olaf Stuve

    Published in Journal of Central Nervous System Disease (2022-08-01)
    Get full text
    Article


  4. 4

    Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease by Guoqiao Wang, Lei Liu, Yan Li, Andrew J. Aschenbrenner, Randall J. Bateman, Paul Delmar, Lon S. Schneider, Richard E. Kennedy, Gary R. Cutter, Chengjie Xiong

    Get full text
    Article


  5. 5

    Ketone monoester attenuates oxygen desaturation during weighted ruck exercise under acute hypoxic exposure but does not impact cognitive performance by Tyler S. McClure, Jeffrey Phillips, Dawn Kernagis, Kody Coleman, Ed Chappe, Gary R. Cutter, Brendan Egan, Todd Norell, Brianna J. Stubbs, Marcas M. Bamman, Andrew P. Koutnik

    Published in Experimental Physiology (2024-10-01)
    Get full text
    Article


  6. 6

    Ketone monoester attenuates declines in cognitive performance and oxygen saturation during acute severe hypoxic exposure under resting conditions by Tyler S. McClure, Jeffrey Phillips, Andrew P. Koutnik, Kody Coleman, Ed Chappe, Gary R. Cutter, Brendan Egan, Todd Norell, Brianna J. Stubbs, Marcas M. Bamman, Dawn Kernagis

    Published in Experimental Physiology (2024-10-01)
    Get full text
    Article


  7. 7

    Genomic copy number variants: evidence for association with antibody response to anthrax vaccine adsorbed. by Michael I Falola, Howard W Wiener, Nathan E Wineinger, Gary R Cutter, Robert P Kimberly, Jeffrey C Edberg, Donna K Arnett, Richard A Kaslow, Jianming Tang, Sadeep Shrestha

    Published in PLoS ONE (2013-01-01)
    Get full text
    Article


  8. 8

    Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2) by Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky

    Published in Neurology and Therapy (2024-07-01)
    Get full text
    Article


  9. 9

    Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma by Kelly M. Makielski, Aaron L. Sarver, Michael S. Henson, Kathleen M. Stuebner, Antonella Borgatti, Lukkana Suksanpaisan, Caitlin Preusser, Alexandru-Flaviu Tabaran, Ingrid Cornax, M. Gerard O’Sullivan, Andrea Chehadeh, Donna Groschen, Kelly Bergsrud, Sara Pracht, Amber Winter, Lauren J. Mills, Marc D. Schwabenlander, Melissa Wolfe, Michael A. Farrar, Gary R. Cutter, Joseph S. Koopmeiners, Stephen J. Russell, Jaime F. Modiano, Shruthi Naik

    Published in Molecular Therapy: Oncolytics (2023-12-01)
    Get full text
    Article


Search Tools: